You just read:

Atox Bio Announces Independent Safety Monitoring Committee Recommendation to Continue Phase 3 Study of Reltecimod in Necrotizing Soft Tissue Infections

News provided by

Atox Bio

Sep 25, 2018, 01:03 ET